Kailera Therapeutics announced on April 14 that it plans to raise up to $533 million through an initial public offering, which could become the largest in the biopharma sector in recent years. The company will offer 33 million shares of common stock at a price range of $14 to $16 per share. In addition, underwriters have a 30-day option to purchase up to five million more shares at the IPO price, potentially increasing total proceeds above $610 million.
This move is significant as it positions Kailera at the forefront of this year's biotech IPOs and reflects renewed investor interest in obesity treatments and biopharmaceutical innovation. If fully realized, this offering would surpass recent high-profile debuts such as Generate:Biomedicines' $400 million IPO and Eikon Therapeutics’ $381 million raise earlier this year.
The funds from the IPO will be combined with Kailera’s previous $600 million series B round raised in October 2025. These resources are intended for advancing its pipeline of obesity drugs into late-stage development. Kailera's lead product is ribupatide, a GLP-1/GIP receptor dual agonist developed with Jiangsu Hengrui Pharmaceuticals from China. Both injectable and oral versions are being pursued after Phase 2 data showed promising weight loss results—12.1% reduction over 26 weeks compared to placebo.
According to its prospectus, Kailera expects about $625 million will fund injectable ribupatide through three ongoing Phase 3 studies into mid-2028, while around $150 million is set aside for developing an oral version with late-stage trials planned for that period as well. The company also has KAI-7535, another daily oral GLP-1 drug targeting obesity; approximately $50 million will support its progress through Phase 2 trials.
Founded in October 2024 with an initial funding of $400 million and assets sourced from China, Kailera has quickly become one of the most talked-about startups using a NewCo model—a method increasingly favored by investors seeking opportunities within Chinese pharmaceutical innovation.
Recent industry activity highlights strong competition for promising obesity therapies: last fall saw Pfizer outbid Novo Nordisk for Metsera in a deal valued near $10 billion. As major players continue investing heavily in new treatments, observers expect continued momentum across both mergers-and-acquisitions activity and public offerings.
